On the Discovery of TOR As the Target of Rapamycin
The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ tra...
Gespeichert in:
| Veröffentlicht in: | PLoS pathogens 2015-11, Vol.11 (11), p.e1005245-e1005245 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1005245 |
|---|---|
| container_issue | 11 |
| container_start_page | e1005245 |
| container_title | PLoS pathogens |
| container_volume | 11 |
| creator | Heitman, Joseph |
| description |
The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ transplant patients. |
| doi_str_mv | 10.1371/journal.ppat.1005245 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1749627741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A436982753</galeid><doaj_id>oai_doaj_org_article_cccef5217c604d86a856a26cc22228a5</doaj_id><sourcerecordid>A436982753</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-81589c0beb59be442d852680e8d17769aea6f66214d0564673a7524e14bcdcbb3</originalsourceid><addsrcrecordid>eNpVUl1r2zAUFWNj7bL9g7EZ9rKXZPqW_DII3VehECjZs7iWr1MHx_Ikp5B_P7lxS6sXiaNzj-65OoR8ZHTFhGHf9uEYe-hWwwDjilGquFSvyCVTSiyNMPL1s_MFeZfSnlLJBNNvyQXXSlJG-SXhm74Y77D40SYf7jGeitAU281tsU4P-BbiDscJvIUBDiff9u_Jmwa6hB_mfUH-_vq5vfqzvNn8vr5a3yy94npcWqZs6WmFlSorlJLXNuOWoq2ZMboEBN1ozZmsqdJSGwEme0AmK1_7qhIL8vmsO3QhudlucszIUnNjspcFuT4z6gB7N8T2APHkArTuAQhx5yCOre_Qee-xUZwZr6msrQarNHDtPc_Lgspa3-fXjtUBa4_9GKF7Ifrypm_v3C7cO6mFNMpmga-zQAz_jphGd8gzxa6DHsNx6lswY7mgZaZ-OVN3kFtr-yZkRT_R3VoKXVpulMgseWb5GFKK2Dw1w6ibIvA4EzdFwM0RyGWfnht5Knr8c_Efp5GsFg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1731782309</pqid></control><display><type>article</type><title>On the Discovery of TOR As the Target of Rapamycin</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Heitman, Joseph</creator><creatorcontrib>Heitman, Joseph</creatorcontrib><description>
The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ transplant patients.</description><identifier>ISSN: 1553-7374</identifier><identifier>ISSN: 1553-7366</identifier><identifier>EISSN: 1553-7374</identifier><identifier>DOI: 10.1371/journal.ppat.1005245</identifier><identifier>PMID: 26540102</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Animals ; Anti-Bacterial Agents - therapeutic use ; Brewer's yeast ; Chemotherapy ; Drugs ; Funding ; Health aspects ; Humans ; Immunosuppressive Agents - therapeutic use ; Kinases ; Mammals ; Medical schools ; Physiological aspects ; Proteins ; Rapamycin ; Research Matters ; Scientists ; Sirolimus - therapeutic use ; Studies ; TOR Serine-Threonine Kinases - drug effects ; Transplants ; Transplants & implants ; Vaccines</subject><ispartof>PLoS pathogens, 2015-11, Vol.11 (11), p.e1005245-e1005245</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Joseph Heitman 2015 Joseph Heitman</rights><rights>2015 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Heitman J (2015) On the Discovery of TOR As the Target of Rapamycin. PLoS Pathog 11(11): e1005245. doi:10.1371/journal.ppat.1005245</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-81589c0beb59be442d852680e8d17769aea6f66214d0564673a7524e14bcdcbb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634758/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634758/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26540102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heitman, Joseph</creatorcontrib><title>On the Discovery of TOR As the Target of Rapamycin</title><title>PLoS pathogens</title><addtitle>PLoS Pathog</addtitle><description>
The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ transplant patients.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Brewer's yeast</subject><subject>Chemotherapy</subject><subject>Drugs</subject><subject>Funding</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kinases</subject><subject>Mammals</subject><subject>Medical schools</subject><subject>Physiological aspects</subject><subject>Proteins</subject><subject>Rapamycin</subject><subject>Research Matters</subject><subject>Scientists</subject><subject>Sirolimus - therapeutic use</subject><subject>Studies</subject><subject>TOR Serine-Threonine Kinases - drug effects</subject><subject>Transplants</subject><subject>Transplants & implants</subject><subject>Vaccines</subject><issn>1553-7374</issn><issn>1553-7366</issn><issn>1553-7374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVUl1r2zAUFWNj7bL9g7EZ9rKXZPqW_DII3VehECjZs7iWr1MHx_Ikp5B_P7lxS6sXiaNzj-65OoR8ZHTFhGHf9uEYe-hWwwDjilGquFSvyCVTSiyNMPL1s_MFeZfSnlLJBNNvyQXXSlJG-SXhm74Y77D40SYf7jGeitAU281tsU4P-BbiDscJvIUBDiff9u_Jmwa6hB_mfUH-_vq5vfqzvNn8vr5a3yy94npcWqZs6WmFlSorlJLXNuOWoq2ZMboEBN1ozZmsqdJSGwEme0AmK1_7qhIL8vmsO3QhudlucszIUnNjspcFuT4z6gB7N8T2APHkArTuAQhx5yCOre_Qee-xUZwZr6msrQarNHDtPc_Lgspa3-fXjtUBa4_9GKF7Ifrypm_v3C7cO6mFNMpmga-zQAz_jphGd8gzxa6DHsNx6lswY7mgZaZ-OVN3kFtr-yZkRT_R3VoKXVpulMgseWb5GFKK2Dw1w6ibIvA4EzdFwM0RyGWfnht5Knr8c_Efp5GsFg</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Heitman, Joseph</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20151101</creationdate><title>On the Discovery of TOR As the Target of Rapamycin</title><author>Heitman, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-81589c0beb59be442d852680e8d17769aea6f66214d0564673a7524e14bcdcbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Brewer's yeast</topic><topic>Chemotherapy</topic><topic>Drugs</topic><topic>Funding</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kinases</topic><topic>Mammals</topic><topic>Medical schools</topic><topic>Physiological aspects</topic><topic>Proteins</topic><topic>Rapamycin</topic><topic>Research Matters</topic><topic>Scientists</topic><topic>Sirolimus - therapeutic use</topic><topic>Studies</topic><topic>TOR Serine-Threonine Kinases - drug effects</topic><topic>Transplants</topic><topic>Transplants & implants</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heitman, Joseph</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS pathogens</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heitman, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>On the Discovery of TOR As the Target of Rapamycin</atitle><jtitle>PLoS pathogens</jtitle><addtitle>PLoS Pathog</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>11</volume><issue>11</issue><spage>e1005245</spage><epage>e1005245</epage><pages>e1005245-e1005245</pages><issn>1553-7374</issn><issn>1553-7366</issn><eissn>1553-7374</eissn><abstract>
The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ transplant patients.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26540102</pmid><doi>10.1371/journal.ppat.1005245</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1553-7374 |
| ispartof | PLoS pathogens, 2015-11, Vol.11 (11), p.e1005245-e1005245 |
| issn | 1553-7374 1553-7366 1553-7374 |
| language | eng |
| recordid | cdi_plos_journals_1749627741 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Animals Anti-Bacterial Agents - therapeutic use Brewer's yeast Chemotherapy Drugs Funding Health aspects Humans Immunosuppressive Agents - therapeutic use Kinases Mammals Medical schools Physiological aspects Proteins Rapamycin Research Matters Scientists Sirolimus - therapeutic use Studies TOR Serine-Threonine Kinases - drug effects Transplants Transplants & implants Vaccines |
| title | On the Discovery of TOR As the Target of Rapamycin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A13%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=On%20the%20Discovery%20of%20TOR%20As%20the%20Target%20of%20Rapamycin&rft.jtitle=PLoS%20pathogens&rft.au=Heitman,%20Joseph&rft.date=2015-11-01&rft.volume=11&rft.issue=11&rft.spage=e1005245&rft.epage=e1005245&rft.pages=e1005245-e1005245&rft.issn=1553-7374&rft.eissn=1553-7374&rft_id=info:doi/10.1371/journal.ppat.1005245&rft_dat=%3Cgale_plos_%3EA436982753%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1731782309&rft_id=info:pmid/26540102&rft_galeid=A436982753&rft_doaj_id=oai_doaj_org_article_cccef5217c604d86a856a26cc22228a5&rfr_iscdi=true |